Boston and Lausanne, Switzerland (ots/PRNewswire) - SOPHiA GENETICS,
leader in Data-Driven Medicine, announced today that Kathy L. Hibbs
was nominated to the company's Board of Directors and its Audit
Committee. Hibbs is an accomplished healthcare technology executive,
currently holding the position of Chief Legal and Regulatory Officer
at 23andMe, the leading consumer genetics and research company.
Regularly recognized as one of the Bay Area's most influential women
by both the San Francisco and Silicon Valley Business Journals, Hibbs
is ranked by Chambers as among the most influential General Counsels
in US. She sits on the boards of Decipher Biosciences, Inc. and Cadex
Genomics Inc. During her 15 years' experience as an executive officer
and corporate secretary for two public biotechnology companies,
Genomic Health, Inc. and Monogram Biosciences, Inc., Hibbs developed
her passion for personalized medicine and the power of innovation to
improve the lives of patients. She is globally recognized for her
effectiveness, having successfully pioneered the first ever FDA
clearance for over-the-counter genetic testing.
"We are pleased to welcome Kathy to SOPHiA's Board of Directors,"
said Jurgi Camblong, SOPHiA GENETICS' CEO and Founder. "The company
will significantly benefit from Kathy's extensive experience in legal
and regulatory affairs in the biotech industry specifically. She
substantially contributed to the accessibility of genetic testing and
usage of real-world evidence data, leading millions of people to more
proactive health decisions, and is therefore totally aligned with our
mission to democratize Data-Driven Medicine."
"SOPHiA's position in the market and its rapid penetration in the US
make it an exciting time to join the company," added Kathy Hibbs. "We
share a common passion and a commitment to bring personalized
medicine to the next chapter of its development; I find it truly
inspiring, and I look forward to bringing my experience to the
This latest appointment follows that of Didier Hirsch, former CFO at
Agilent. Hirsch joined SOPHiA's Board of Director in October 2020 and
chairs the Audit Committee Hibbs will be a part of. These nominations
take place in a wider context of professionalization of the company,
to ensure consistency with the increasing regulation of an industry
in constant growth.
About SOPHiA GENETICS
SOPHiA GENETICS is a health tech company democratizing Data-Driven
Medicine to improve health outcomes and economics worldwide. By
unlocking the power of new-generation health data for cancer and rare
diseases management, the universal SOPHiA Platform allows clinical
researchers to act with precision and confidence. The company's
innovative approach enables an ever-expanding community of over 1,000
institutions to benefit from knowledge sharing, fostering a new era
in healthcare. SOPHiA's achievement is recognized by the MIT
Technology Review's "50 Smartest Companies."
More info: SOPHiAGENETICS.COM, follow @SOPHiAGENETICS on Twitter.
Global Media Contact:
PR & Communications Manager
+41 79 863 11 10
Digital press kit: http://www.ots.at/pressemappe/PR114431/aom
Aktien auf dem Radar:Frequentis, Marinomed Biotech, Zumtobel, Kapsch TrafficCom, Warimpex, Agrana, Flughafen Wien, Addiko Bank, Cleen Energy, UBM, Linz Textil Holding, AMS, AT&S, CA Immo, DO&CO, FACC, Immofinanz, Palfinger, Rath AG, Rosenbauer, SBO, S Immo, Wolford, Porr, Frauenthal, Strabag, Oberbank AG Stamm, Österreichische Post, voestalpine, Polytec Group, Daimler.
Erste Asset Management
Die Erste Asset Management versteht sich als internationaler Vermögensverwalter und Asset Manager mit einer starken Position in Zentral- und Osteuropa. Hinter der Erste Asset Management steht die Finanzkraft der Erste Group Bank AG. Den Kunden wird ein breit gefächertes Spektrum an Investmentfonds und Vermögensverwaltungslösungen geboten.
>> Besuchen Sie 60 weitere Partner auf boerse-social.com/partner
Mehr aktuelle OTS-Meldungen HIER